SUVEN LIFE SCIENCES LTD
FIRST QUARTER RESULTS
Q1 FY2013
SUVEN LIFE SCIENCES is a smaller Pharma Firm, which is progressing gradually each quarter.
Here are its results for the first quarter ending June 2012.
HIGH LIGHTS
Net Sales for Q1 FY 13 stands at Rs.70.53 Cr; up by 12.82% from the previous quarter of Q4 FY 12 (Rs.62.51 Cr); and up by 58.02 % from the corresponding Quarter of Q1 FY 12 (Rs.44.63 Cr).
Total Expenditure for Q1 FY 13 stands at Rs.59.02 Cr; up by 16.04% from the previous quarter of Q4 FY 12 (Rs.50.86 Cr); and up by 44.49% from the corresponding Quarter of Q1 FY 12 (Rs. 40.85 Cr).
Profit before Interest, Dep. & Taxes for Q1 FY 13 stands at Rs.11.50 Cr; down by -1.25% from the previous quarter of Q4 FY 12 (Rs.11.65 Cr); and up by 204.06% from the corresponding Quarter of Q1 FY 12 (Rs. 3.38 Cr).
Net Profit for Q1 FY 13 stands at Rs.7.96 Cr; down by -4.12% from the previous quarter of Q4 FY 12 (Rs.8.31 Cr); and up by 136.94% from the corresponding Quarter of Q1 FY 12 (Rs. 3.36 Cr).
Diluted EPS for Q1 FY 13 stands at Rs.0.68 ; Rs.0.71 in Q4 FY 12; Rs.0.29 in Q1 FY12 on a Face Value of Rs.1.
52 week high/low price : 18.90/11.10; Current Market price is also around Rs.18.30.
Paid-up Equity is low at 11.67 Cr; Of this Public Holding is around 36.56%.
Suven claims to achieve a number of discoveries and patents periodically. Its Sales and profits are improving gradually from quarter to quarter. This will be an interesting company to watch.
RESULTS TABLE
Suven Life Sciences
|
30-Jun-12
|
QoQ % Dif
|
31-Mar-12
|
YoY%dif
|
30-Jun-11
|
31-Dec-11
|
30-Sep-11
|
Net Sales
|
7052.72
|
12.82
|
6251.37
|
58.02
|
4463.29
|
4863.7
|
4804.38
|
Total Expenditure
|
5902.25
|
16.04
|
5086.33
|
44.49
|
4084.92
|
4944.58
|
4705.95
|
Profit before Interest, Dep. & Taxes
|
1150.47
|
-1.25
|
1165.04
|
204.06
|
378.37
|
-80.88
|
98.43
|
Net Profit
|
796.34
|
-4.12
|
830.55
|
136.94
|
336.09
|
129.45
|
256.12
|
Diluted EPS
|
0.68
|
-4.23
|
0.71
|
134.48
|
0.29
|
0.11
|
0.22
|
Net Sales
|
7052.72
|
12.82
|
6251.37
|
58.02
|
4463.29
|
4863.7
|
4804.38
|
Cost of materials consumed
|
2144.63
|
-12.99
|
2464.72
|
15.67
|
1854.11
|
2125.68
|
1678.55
|
Employee benefits
|
651.73
|
29.43
|
503.54
|
38.23
|
471.47
|
583.66
|
594.21
|
Depreciation
|
183.23
|
33.46
|
137.29
|
32.08
|
138.73
|
138.27
|
140.02
|
Other expenses
|
2591.82
|
68.86
|
1534.92
|
58.89
|
1631.23
|
2976.45
|
2385.9
|
Total expenses
|
5902.25
|
16.04
|
5086.33
|
44.49
|
4084.92
|
4944.58
|
4705.95
|
Profit before tax
|
881.02
|
-2.35
|
902.25
|
274.79
|
235.07
|
-138.12
|
67.74
|
Tax Expenses
|
84.68
|
18.1
|
71.7
|
-183.82
|
-101.02
|
-267.57
|
-188.38
|
Net Profit
|
796.34
|
-4.12
|
830.55
|
136.94
|
336.09
|
129.45
|
256.12
|
Face Value(Rs )
|
1
|
0
|
1
|
0
|
1
|
1
|
1
|
Paid-up Equity
|
1167.32
|
0
|
1167.32
|
0
|
1167.32
|
1167.32
|
1167.32
|
Diluted EPS
|
0.68
|
-4.23
|
0.71
|
134.48
|
0.29
|
0.11
|
0.22
|
Public holding (%)
|
36.56
|
0
|
36.56
|
-0.44
|
36.72
|
36.56
|
36.86
|
* * * E N D * *
No comments:
Post a Comment